AU2017290703B2 - Formulations of brincidofovir - Google Patents

Formulations of brincidofovir Download PDF

Info

Publication number
AU2017290703B2
AU2017290703B2 AU2017290703A AU2017290703A AU2017290703B2 AU 2017290703 B2 AU2017290703 B2 AU 2017290703B2 AU 2017290703 A AU2017290703 A AU 2017290703A AU 2017290703 A AU2017290703 A AU 2017290703A AU 2017290703 B2 AU2017290703 B2 AU 2017290703B2
Authority
AU
Australia
Prior art keywords
brincidofovir
concentration
clear
colorless
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017290703A
Other languages
English (en)
Other versions
AU2017290703A1 (en
Inventor
Irma Marisa Grossi
Mohammed Anowrul KABIR
Odin Johann Naderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Biodefense Operations Lansing Inc
Original Assignee
Emergent Biodefense Operations Lansing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Biodefense Operations Lansing Inc filed Critical Emergent Biodefense Operations Lansing Inc
Publication of AU2017290703A1 publication Critical patent/AU2017290703A1/en
Assigned to EMERGENT BIODEFENSE OPERATIONS LANSING LLC reassignment EMERGENT BIODEFENSE OPERATIONS LANSING LLC Request for Assignment Assignors: CHIMERIX, INC.
Application granted granted Critical
Publication of AU2017290703B2 publication Critical patent/AU2017290703B2/en
Priority to AU2023204117A priority Critical patent/AU2023204117B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017290703A 2016-06-28 2017-06-28 Formulations of brincidofovir Active AU2017290703B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023204117A AU2023204117B2 (en) 2016-06-28 2023-06-28 Formulations of brincidofovir

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662355844P 2016-06-28 2016-06-28
US62/355,844 2016-06-28
US201662394665P 2016-09-14 2016-09-14
US62/394,665 2016-09-14
US201762446213P 2017-01-13 2017-01-13
US62/446,213 2017-01-13
US201762465053P 2017-02-28 2017-02-28
US62/465,053 2017-02-28
US201762507397P 2017-05-17 2017-05-17
US62/507,397 2017-05-17
US201762512825P 2017-05-31 2017-05-31
US62/512,825 2017-05-31
PCT/US2017/039804 WO2018005676A1 (en) 2016-06-28 2017-06-28 Formulations of brincidofovir

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023204117A Division AU2023204117B2 (en) 2016-06-28 2023-06-28 Formulations of brincidofovir

Publications (2)

Publication Number Publication Date
AU2017290703A1 AU2017290703A1 (en) 2018-12-13
AU2017290703B2 true AU2017290703B2 (en) 2023-03-30

Family

ID=59313330

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017290703A Active AU2017290703B2 (en) 2016-06-28 2017-06-28 Formulations of brincidofovir
AU2023204117A Active AU2023204117B2 (en) 2016-06-28 2023-06-28 Formulations of brincidofovir

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023204117A Active AU2023204117B2 (en) 2016-06-28 2023-06-28 Formulations of brincidofovir

Country Status (12)

Country Link
US (3) US20170368082A1 (enExample)
EP (2) EP4295853A3 (enExample)
JP (3) JP6878473B2 (enExample)
CN (4) CN118416082A (enExample)
AU (2) AU2017290703B2 (enExample)
CA (1) CA3024886A1 (enExample)
DK (1) DK3474822T3 (enExample)
ES (1) ES3037596T3 (enExample)
FI (1) FI3474822T3 (enExample)
PL (1) PL3474822T3 (enExample)
PT (1) PT3474822T (enExample)
WO (1) WO2018005676A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073148A1 (en) 2013-11-15 2015-05-21 Chimerix Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters
CN118416082A (zh) * 2016-06-28 2024-08-02 应急生物防御行动兰辛有限责任公司 布林西多福韦的制剂
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CN114073772A (zh) * 2020-08-18 2022-02-22 上海市公共卫生临床中心 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途
CN114558022B (zh) * 2022-02-16 2023-11-17 华中农业大学 布林西多福韦在制备抗伪狂犬病毒药物中的应用
CN114732821A (zh) * 2022-04-24 2022-07-12 华中农业大学 西多福韦的前药在制备防治非洲猪瘟药物中的应用
JP7417339B1 (ja) * 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療
WO2025072782A1 (en) * 2023-09-29 2025-04-03 Symbio Pharmaceuticals Limited Brincidofovir for treatment of multiple sclerosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133966A1 (en) * 2007-04-27 2008-11-06 Chimerix, Inc. Methods of reducing nephrotoxicity in subjects administered with nucleoside

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005490A (es) 1999-12-03 2004-09-10 Univ California San Diego Compuestos de fosfonato.
JP4136340B2 (ja) * 2000-08-18 2008-08-20 武田薬品工業株式会社 注射剤
JP2008538354A (ja) 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
JP2011116658A (ja) 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 豚萎縮性鼻炎用薬剤の製造方法
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
AU2010279678B2 (en) 2009-08-03 2015-09-10 Emergent Biodefense Operations Lansing Llc Composition and methods of treating viral infections and viral induced tumors
CA2779473C (en) 2009-10-30 2016-08-16 Chimerix, Inc. Methods of treating viral associated diseases
ES2547698T3 (es) 2009-12-03 2015-10-08 Jiangsu Hengrui Medicine Co., Ltd. Liposoma de irinotecán o su clorhidrato y método de preparación del mismo
US20110263536A1 (en) 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases
CN103209985B (zh) 2010-08-31 2016-08-24 奇默里克斯公司 膦酸酯衍生物及其合成方法
EP2770834A4 (en) * 2011-10-26 2015-11-25 Chimerix Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
WO2013163509A1 (en) 2012-04-27 2013-10-31 Chimerix, Inc. A method of mitigating virus associated end-organ damage
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015073148A1 (en) * 2013-11-15 2015-05-21 Chimerix Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters
CN118416082A (zh) * 2016-06-28 2024-08-02 应急生物防御行动兰辛有限责任公司 布林西多福韦的制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133966A1 (en) * 2007-04-27 2008-11-06 Chimerix, Inc. Methods of reducing nephrotoxicity in subjects administered with nucleoside

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIESLA S L ET AL: "Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 59, no. 3, 2003, pages 163 - 171, *
FEIYAN MA ET AL: "Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS., vol. 89, 2015, NL, pages 271 - 279 *

Also Published As

Publication number Publication date
ES3037596T3 (en) 2025-10-03
WO2018005676A1 (en) 2018-01-04
PT3474822T (pt) 2025-08-21
CN118416082A (zh) 2024-08-02
FI3474822T3 (fi) 2025-08-15
JP7221485B2 (ja) 2023-02-14
PL3474822T3 (pl) 2025-11-03
AU2023204117A1 (en) 2023-07-13
EP4295853A3 (en) 2024-03-06
JP2023033538A (ja) 2023-03-10
EP3474822B1 (en) 2025-07-09
DK3474822T3 (da) 2025-08-18
US12485131B2 (en) 2025-12-02
CN119139329A (zh) 2024-12-17
CA3024886A1 (en) 2018-01-04
JP6878473B2 (ja) 2021-05-26
JP2019519570A (ja) 2019-07-11
CN109475497A (zh) 2019-03-15
JP7407984B2 (ja) 2024-01-04
AU2017290703A1 (en) 2018-12-13
US20200138835A1 (en) 2020-05-07
JP2021143178A (ja) 2021-09-24
AU2023204117B2 (en) 2025-03-20
EP3474822A1 (en) 2019-05-01
CN114569547A (zh) 2022-06-03
EP4295853A2 (en) 2023-12-27
US20170368082A1 (en) 2017-12-28
US20230210873A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
AU2023204117B2 (en) Formulations of brincidofovir
US20200338199A1 (en) Sodium chloride solution for drug reconstitution or dilution
HK1245090A1 (en) Sodium chloride solution for drug reconstitution
US20200345636A1 (en) Artificial Vitreous Humor for the Investigation of Drugs and Drug Formulations
HK40105712A (en) Formulations of brincidofovir
HK40075964A (en) Formulations of brincidofovir
PETERSEN et al. Digoxin–trimethoprim interaction
KR20230127252A (ko) 5-ht3 수용체 길항제와 조합된 nk1 길항제 전구약물화합물의 용도
Bayer et al. BASF SE APD/E
HK40020909A (en) Sodium chloride solution for drug reconstitution or dilution
James et al. The intravenous toxicity of dibekacin sulphate (DKB) to female beagle dogs
HK1119970B (en) Sodium chloride solution for drug reconstitution or dilution

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EMERGENT BIODEFENSE OPERATIONS LANSING LLC

Free format text: FORMER APPLICANT(S): CHIMERIX, INC.

FGA Letters patent sealed or granted (standard patent)